Book a meeting
DO-BO

How Can Startups Leverage Market Access to Attract Investors, Johan Olsson?

In the latest episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer sits down with Johan Olsson, a seasoned life sciences investor, to uncover the critical role of market access and reimbursement in early-stage healthcare investments.

They explore how early market access planning impacts healthcare startups, investment decisions, and commercialization success. Discover why pricing, reimbursement, and payer strategies are key to securing funding, mitigating risk, and maximizing valuation. An understanding of the market access landscape can make or break a healthcare startup’s valuation, funding potential, and commercial viability. Tune in now to learn how to navigate market access for healthcare investments!

Related

Why Should Early Health Economics Move Upstream, Dr. Björn Schwander & Julie Frappier?

By

Stefan Walzer

By the time most health economists get pulled in, the recipe is already set. In this episode of MAP — the Market Access Podcast, Dr. Stefan Walzer sits down with two industry veterans — Dr. Björn Schwander, Founder of AHEAD GmbH and a specialist in early health economic modeling, and Julie Frappier, senior health economist […]

How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali? (Repost)

By

Stefan Walzer

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

Is the EU “Launch Obligation” Really as Scary as It Sounds, Dr. Alexander Natz?

By

Stefan Walzer

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]